Sign In
Buy BBH
$181.73
-4.21 (-2.26%)
At Close: Jun 02, 2026
Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause
05:55pm, Tuesday, 13'th Apr 2021
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administratio
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
06:10pm, Thursday, 08'th Apr 2021
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Biotech Shined with Vaccines. It Can Do It Again with ‘BBH'
11:30am, Wednesday, 03'rd Mar 2021
The United States and China have been locking horns when it comes to technological advances. ETF investors looking to capitalize on strength in U.S. biotech should give the VanEck Vectors® Biotech ET
10 ETFs to Buy to Mimic 2021's Best Stock Picks
03:00pm, Wednesday, 24'th Feb 2021
Investors looking to reduce the risk of owning some of 2021's best stocks might consider these 10 ETFs to buy instead. The post 10 ETFs to Buy to Mimic 2021's Best Stock Picks appeared first on Invest
Illumina Earnings, Forward Guidance Strengthen Biotech ETFs
03:38pm, Friday, 12'th Feb 2021
Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the VanEck
How Will Biotech ETFs React to These Q4 Earnings Releases?
03:54pm, Friday, 05'th Feb 2021
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
02:18pm, Tuesday, 12'th Jan 2021
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
11:17am, Tuesday, 15'th Dec 2020
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
08:29am, Monday, 14'th Dec 2020
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexi
How Will Vaccine Arrivals Affect Biotech ETFs?
04:17pm, Monday, 30'th Nov 2020
November has been a big month for stock and biotech ETFs, and with the Federal Aviation Administration announcing that it supported the “first mass air shipment” of coronavirus vaccines on Friday,
Bullish on Biotech? The BBH ETF is Not Just a 2020 Play
12:04pm, Thursday, 19'th Nov 2020
The COVID-19 pandemic has given way to new technological innovations in the biotechnology sector with respect to creating a vaccine. ETF investors looking for a play that can take them well into 2021
Will Moderna Vaccine News Boost Biotech ETFs?
03:30pm, Thursday, 12'th Nov 2020
Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech,
Can't Get Enough Biotech Exposure in Your Portfolio?
12:38pm, Thursday, 29'th Oct 2020
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds
Biotech ETFs at multi-week highs, extending winning streak
01:45pm, Tuesday, 27'th Oct 2020
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo
Is COVID-19 An Impetus For ESG Investing?
07:00am, Wednesday, 02'nd Sep 2020
The primary driver of doing ESG is risk mitigation and COVID-19 pushed environmental and societal issues higher up the risk spectrum.
